Key facts
- · Type: New offering first sale 2025-12-22 · Amount sold: $1.51M · Total offering: $2M · SEC filing
- · Type: New offering first sale 2025-09-29 · Amount sold: $2.99M · Total offering: $7M · SEC filing
- · Type: Filing · SEC filing
- · Type: Filing · SEC filing
- · Type: Filing · SEC filing
Is MAIA Biotechnology, Inc. a real, registered company?
MAIA Biotechnology, Inc. is a registered filer with the SEC (CIK 1878313) and has filed since 2023-11-29. 7 filings are on record, the latest on 2026-01-05.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has MAIA Biotechnology, Inc. raised?
Its new offerings report $4.50M sold across 2 offerings, as its own filings state.
Run the free check on MAIA Biotechnology, Inc. →
CHICAGO, ILLINOIS
Biotechnology
7
$4.50M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-01-05 | New offering first sale 2025-12-22 | $1.51M | $2M | SEC filing |
| 2025-10-14 | New offering first sale 2025-09-29 | $2.99M | $7M | SEC filing |
| 2025-06-11 | Filing | — | — | SEC filing |
| 2025-03-04 | Filing | — | — | SEC filing |
| 2024-11-12 | Filing | — | — | SEC filing |
| 2024-03-21 | Filing | — | — | SEC filing |
| 2023-11-29 | Filing | — | — | SEC filing |
Keep reading
More on MAIA Biotechnology, Inc. and the records around it.
MAIA Biotechnology, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Jan 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Solas Capital Management, LLC also filed stake reports on 5 other companies: FENNEC PHARMACEUTICALS INC. (Aug 2026), Modular Medical, Inc. (Aug 2026), SANUWAVE Health, Inc. (Aug 2026)
Watch MAIA Biotechnology, Inc.
Get an email when MAIA Biotechnology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with MAIA Biotechnology, Inc.?
Who to contact
- Vlad Vitoc — Chief Executive Officer, President and Chairman of the Board of Directors
- Jeffrey Himmelreich — Head of Finance
- Sergei Gryaznov — Chief Scientific Officer
- Jean-Manasse Theagene — Director
- Steven Chaouki — Director
- Stan Smith — Director
- Ramiro Guerrero — Director
- Louie Yee — Director
- Cristian Luput — Director
- Round: Form D filed 2026-01-05
- Amount sold: $1.51M
- Industry: Biotechnology
- Based: CHICAGO, ILLINOIS
People listed
- Vlad Vitoc — Chief Executive Officer, President and Chairman of the Board of Directors
- Jeffrey Himmelreich — Head of Finance
- Sergei Gryaznov — Chief Scientific Officer
- Jean-Manasse Theagene — Director
- Steven Chaouki — Director
- Stan Smith — Director
- Ramiro Guerrero — Director
- Louie Yee — Director
- Cristian Luput — Director
- Filing: Form D filed 2026-01-05
- Amount sold: $1.51M
- Industry group: Biotechnology
- Based: CHICAGO, ILLINOIS
- Entity type: Corporation
We'll show it in your MentionFox inbox when MAIA Biotechnology, Inc. raises, hires or launches. No email unless you switch it on.
Watch MAIA Biotechnology, Inc. →Want the whole picture on MAIA Biotechnology, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on MAIA Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MAIA Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from MAIA Biotechnology, Inc.'s own filings with the SEC. The people those filings name are on the team page.